Genotype-Phenotype correlation of 17 cases of Pompe Disease in Spanish Patients and Identification of 4 Novel Mutations

Paula Hernandez-Arevalo
Virgen del Rocio University Hospital: Hospital Universitario Virgen del Rocio

Jose D. Santotoribio
Virgen del Rocio University Hospital: Hospital Universitario Virgen del Rocio

Rocio Delarosa-Rodriguez
Virgen del Rocio University Hospital: Hospital Universitario Virgen del Rocio

Antonio Gonzalez-Meneses
Virgen del Rocio University Hospital: Hospital Universitario Virgen del Rocio

Salvador Garcia-Morillo
Virgen del Rocio University Hospital: Hospital Universitario Virgen del Rocio

Pilar Jimenez-Arriscado
Virgen del Rocio University Hospital: Hospital Universitario Virgen del Rocio

juan M Guerrero
Virgen del Rocio University Hospital: Hospital Universitario Virgen del Rocio

Hada C. Macher (hadacmacher@icloud.com)
Universitary Hospital Virgen del Rocío de sevilla

Research

Keywords: Pompe Disease, genotype-phenotype correlation, GAA gene, alpha-glucosidase enzyme.

Posted Date: December 23rd, 2020

DOI: https://doi.org/10.21203/rs.3.rs-133653/v1

License: ☺ ① This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Pompe disease (PD) is an autosomal recessive metabolic disorder caused by mutations in the acid α-glucosidase gene (GAA) that produces defects in the lysosomal α,1,4-glucosidase. We aimed to identify genetic variations and clinical features in Spanish subjects to establish genotype-phenotype correlation.

**Methods:** A total of 2709 subjects who showed symptoms or susceptible signs of PD were enrolled in this observational study. Enzymatic activity was detected by fluorometric techniques and the genetic study was carried out using Next-Generation Sequencing.

**Results:** Fourteen different variants from seventeen patients were identified, four of whom had not been described in the literature previously, including a homozygous variant. In all of them α-glucosidase activity was decreased. Muscle weakness, respiratory distress, exercise intolerance, hypotonia, dysphagia and myalgia were commonly observed in patients.

**Conclusions:** This study report four new mutations that contribute to the mutation spectrum of the GAA gene. We confirm that patients in Spain have a characteristic profile of a European population, with c.-32-13T>G being the most prevalent variant. Furthermore, it was confirmed that the c.236_246delCCACACAGTGC mutation in homozygosis is associated with early disease and a worse prognosis.

Background

Pompe disease (PD) is an autosomal recessive metabolic disorder caused by mutations in the acid alpha-glucosidase gene (GAA) that produces biochemical defects in the lysosomal acid alpha 1,4-glucosidase. The deficient activity of the enzyme leads to lysosomal accumulation of glycogen in all tissues, specially skeletal muscle. PD is a disorder that manifests a clinical spectrum that varies regarding the age of onset, the rate of disease progression, and the degree of organ involvement; and in general, there is an inverse correlation between the severity of the disease and the level of residual enzyme activity. Because of the variation in the phenotypes, PD is classified into infantile-onset Pompe disease (IOPD) and late-onset Pompe disease (LOPD). IOPD is characterized by onset during the first year of life with hypertrophic cardiomyopathy, generalized muscle weakness, hepatomegaly and respiratory dysfunction. LOPD is characterized by onset in childhood or adulthood and the presence of slow progressive muscle weakness, cardiomyopathy and respiratory distress. The incidence of the disease varies in different ethnic groups and for different clinical forms. It was reported that the incidence of PD in Caucasian is 1:100000 and 1:60000 in IOPD and LOPD respectively [1]

The GAA gene (OMIN 606800) is situated on chromosome 17 and contains 20 exons and 19 introns extended over a distance of 20Kb. The first exon is noncoding and the beginning of the start codon is at position 33 of exon 2. To date, over 560 variants have been described in the GAA gene. Most of the variants described are marked as pathological and some of them have uncertain significance. Some mutation are widely found in certain populations. For instance, the intronic variant c.-32-13T>G is the most common in Caucasian individuals [2] In Asian population the most common variants are c.1935C>A and c.2238G>C in Taiwanese and Chinese individuals [3], c.1316T>A and c.1857C>G in Korean individuals and c.2560C>T is the most frequent in Afro-American individuals [4]

We report here an observational study as a result of a biochemical and genetic analysis of subjects suggestive of PD. We analyzed clinical manifestations, GAA activity and GAA mutations of Spanish patients with Pompe disease to establish genotype-phenotype correlation.

Materials And Methods

**Design of the study and patients**

In this observational study, clinical and biochemical aspects and GAA gene sequence in a large cohort of patients from different Spanish hospitals were analyzed.
Patients included either had a family member with PD or presented more than one sign or symptom associated to PD: generalized muscle weakness, CK elevations, exercise intolerance or pain, hipotonia, hypertrophic cardiomyopathy, respiratory distress, dysphagia, dyspnoea. Enzyme activity in DBS [Dried blood spots] was measured for each patient. Patients with decreased enzyme activity in DBS underwent lymphocyte determination to confirm the enzyme diagnosis. The sequencing of the GAA gene was performed in the patients who showed low enzyme activity in DBS and lymphocytes or who had a family member with PD.

Informed consent was signed by all patients and the study was approved by the Ethics and Research Committee of the Virgen Macarena and Virgen del Rocio University Hospital (Code: 0826-N-15).

**BioChemical analysis**

The determination was carried out according to the technique described by Chamoles et al. [5]. GAA activity was measured in DBS samples or isolated lymphocytes using 4-Methylumbelliferyl-a-D-glucopyranoside as sustrate and acarbose as inhibitor of competing enzymes at pH 4 [6, 7].

A standard curve of 4-methylumbelliferon allow to establish a relationship between the intensity of the fluorescence and the enzymatic activity as umol/L/h in DBS [cut off < 0.75 umol/L/h] and nmol/min/mg protein in lymphocytes (cut off < 0.15 nmol/min/mg protein).

**Molecular and bioinformatics analysis**

Genomic DNA was isolated from whole blood by standard procedures using MagNA Pure Compact Nucleic Acid Isolation Kit I. (Roche Diagnostics, Basle, Switzerland). Genetic study was carried out by Next-generation sequencing (NGS). All coding regions and classical splicing sites of GAA gene were amplified using a custom design kit for Ion AmpliSeq in a S5 Ion Torrent Platform. The reads were aligned to Genome Reference Consortium Human Build 37 GRCh37. The limitations of the technique include non-detection in the intronic regions of the gene, nor highly repeated regions or other structural variants as inversions, translocations, large insertions or deletions.

Obtained sequences were compared with the GAA reference sequence NM_000152.3 to identify genetic variants. All of them had a minimum read depth of 20x. Single nucleotide changes, insertions or deletions were compared to the online genome databases ClinVar and Human Gene Mutation Database (HGMD) open access and to the Erasmus MC University Medical Center Rotterdam.

After analyzing the numerous variants obtained, those with a frequency greater than 1% in the general population were discarded according to the polymorphism database [http://www.ncbi.nlm.nih.gov/projects/SNP/]. Variants that were described as benign, probably benign or polymorphisms in databases were not further researched. Novel missense mutation effects were determined using in silico analysis by Mutation Taster [http://www.mutationtaster.org] and Polyphen2 software programs [http://genetics.bwh.harvard.edu/pph2]. Novel nonsense mutation that generates a premature stop codon upstream of another known disease causing nonsense mutation or that affects the active protein center were assessed pathogenic.

**Results**

From August 2016 to December 2019 were tested 2637 samples of 1343 males and 1294 females [mean age 45.16 years, SD 20.77, range 0–98]. Patients with positive screening in DBS (activity < 0.75 µmol/L/h) are asked for a sample of lymphocytes to measure the enzyme activity and confirm the diagnosis (activity < 0.15 nmol/min/mg protein). The GAA sequence was performed in all patients whose enzyme activity measured in DBS and lymphocytes was decreased (Fig. 1).

**Enzymatic GAA activity**

Of the 2637 patients studied, 2520 (95,56%) showed normal α-glucosidase activity in DBS. The determination of the enzyme activity in lymphocytes was carried out in the 117 (4,44%) patients who showed low activity in DBS to confirm the enzyme diagnosis. The analysis of the enzyme activity in lymphocytes was normal in 93 (3,53% of total studied and 79,5% of 117 positives in screening) patients and a total of 24 (0,91% of total studied and 20,5 of 117 positives in screening) patients resulted with reduced activity and they were all sequenced.

**GAA mutations**

In relation to 24 sequenced, 17 subjects (#1 to #17), presented two variants compatible with disease: seven males and nine females with LOPD (mean age 36,07, SD 20,57, range 7–64) and a 2-day-old boy with IOPD. Subjects with two variants found will be called
patients”. Subjects #18 and #19, a woman and a man respectively, showed a single variant in heterozygosis (#18 and #19) and in 5 subjects no genetic justication was found in this study. All the variants found in the molecular study were consulted in the bibliography and public databases and were subsequently analyzed using in silico tools if it was possible.

Of all the patients who showed two variants compatible with PD, 4 subjects were homozygous and the rest had two variants in heterozygosity. The clinical manifestations, biochemical analysis data and genotype of the 17 patients from 16 families are summarized in Table 1. Sixteen different variants were detected and the frequency in our population is shown in Table 2. The variants found including 10 missense mutations (11/36; 30.5%), one nonsense mutation (1/36; 2.8%), 2 frameships by deletions (4/36; 11.1%) and one frameship by insertion (2/36; 5.5%), 2 splicing variants (18/36; 50%).

**Clinical manifestations**

Among the 17 patients with PD included in the study, one patient had IOPD phenotype and 16 had LOPD phenotype. The most frequent symptoms and sings in LOPD were muscle weakness (62,5%), followed by high CPK serum values (37,5%) and respiratory distress (25%). Cardiomyopathy, exercise intolerance, hypotonia, dysphagia and myalgia were ascertained in 12.5% of patients. Patient #2, #3 and #6 were asymptomatic at the time of assessment. They were incorporated in the study because they had a member of the family with PD.

The only patient with IOPD, a male of two days of age (patient #1) presented at birth a hypertrophic cardiomyopathy and he died shortly after receiving the sample.

The mean of GAA activity in LOPD patients was 0.30 umol/L/h in DBS and 0.05 nmol/min/mg protein in the isolated lymphocytes. Enzyme activity in DBS of the only infantile-onset Pompe disease patient was 0.5 umol/L/h and lymphocyte measurement could not be performed due to the death of the patient.

**Genotype-Phenotype correlations**

Two mutations were the most frequent, contributing to 58% of the total alleles. The most common variant was c.-32-13T > G. It was detected in 15 patients (88.2%); 2 were homozygotes and 13 were heterozygotes. The next most frequent variant was c.236_246delCCACACAGTCG which was observed in two unrelated patients [5.8%]. One patient was homozygote who presented IOPD and one heterozygote who presented LOPD. The mutations c.1328A > T and c.1396_1397insG were identified in one homozygote and two heterozygotes patients respectively. The rest of the mutations (c.281_282delCT; c.655G > A; c.875A > G; c.925G > A; c.1655T > C; c.2104C > T; c.2237G > C) were detected once in each patient who presented the variant. The total number of mutations detected were analyzed by bibliography and in silico predictive tools [Table 3].

Four of the 14 different variants identified had not been reported previously and we considered them as likely pathogenic (c.1328A > T, c.1831G > A, c.2819C > A, c.1889-1G > A):

The missense variant c.1328A > T is located in exon 9 and it was found in homozygosis in patient #5. It results in a protein change and replaces aspartic acid with valine at codon 443 (p.Asp443Val). All of in silico tools consulted predicted a damaging effect of the variant on the protein function. Mutation Taster consider it as disease causing and Polyphen-2 as probably damaging. Evolutionary conservation of amino acid and the position of the residue involved in the structure of the protein is showed in Fig. 3. This variant was observed in homozygosis in a seventeen woman of Pakistani origin who showed exercise intolerance, muscle weakness and high Creatine-Phosphokinase (CPK) serum values. She also had a muscle biopsy compatible with PD. Enzymatic activity measured in DBS was 0.37 umol/L/h (V.N:>0,75 umol/L/h) and 0.02 nmol/min/mg protein in lymphocytes.

The missense variant c.1831G > A is located in exon 9 and it was found in homozygosis in patient #4. It produces a change in the protein and replaces glycine with serine at codon 611 [p.Gly611Ser]. The analysis with in silico predictive tools showed a probably damaging effect on the protein function. Mutation Taster consider it as disease causing and Polyphen-2 as probably damaging. Evolutionary conservation of amino acid and the position of the residue involved in the structure of the protein is showed in Fig. 3. The variant was observed in homoyzgosis in a seventeen woman of Pakistani origin who showed exercise intolerance, muscle weakness and high Creatine-Phosphokinase (CPK) serum values. She also had a muscle biopsy compatible with PD. Enzymatic activity measured in DBS was 0.16 umol/L/h [V.N:>0,75 umol/L/h] and 0.03 nmol/min/mg protein in lymphocytes.

The novel nonsense variant c.2819C > A is located in exon 20 and it was detected in heterozygosis in patient #9. It leads to a premature stop codon in protein synthesis [p.Ser940Ter]. Pathogenicity of the novel mutation was also predicted by in silico analysis. It was
classified as disease causing by Mutation Taster. The variant was found in a heterozygosis (c.-32-13T > G + c.2819C > A) in a forty-four female who presents hypertrophic cardiomyopathy and respiratory distress. Enzymatic activity measured in DBS was 0.34 umol/L/h (V:N>0,75 umol/L/h).

The splicing variant c.1889-1G > A is located in intron 13 and it was observed in heterozygosis in patient #12. This variant affects the normal splicing process. Bioinformatics analysis were performed using Human Splicing Finder which reported that the variant disturbs the wild type acceptor site probably affecting the splicing. The other allele contained the mutation c.-32-13T > G, widely described as a pathogenic variant. Patient #12 is a fifty-two years old man who presents severe clinical manifestations: exercise intolerance, generalized muscle weakness and respiratory distress. Enzimatic GAA activity was also measured on DBS and lymphocites (0.48 umol/L/h and 0.01 nmol/min/mg protein respectively).

Variants detected in patients who showed a single variant in heterozygosis were c.854C > G and c.2065G > A. Both are missense variant and were not found in other patients. Variant c.854C > G is located in exon 4 and and it is detected in an asymptomatic female. Variant c.2065G > A is located in exon 15 in a male who presents muscle weakness and high level of CPK in serum. Both have been previously reported as pathological and in conflicts of interpretation respectively.

**Discussion**

The proportion of patients with PD from the ones on suspicion of PD in other similar studies in caucasic population was 0.29% [8] and 2.2% [9]. In our population, we tested 2637 samples with suspicion and a total of 17 new patients of PD were found (0.64%).

The median age at diagnosis in this set of patients was 38 years, this is in line with other authors who maintain that clinical manifestations in LOPD may present from the first decade to the seventh decade of life and the median age at diagnosis is 38 years [10, 11]. In our population, three patients were asymptomatic [patients #2, #3 and #6]. All of them were included in the study because they had a family member with PD and they probably show no clinical symptoms because they are still too young. Patient #2 and patient #3 are sisters and they are seven and nine years old respectively and patient #6 is a nineteen year old female. The early diagnosis of LOPD in asymptomatic subjects is rare and it may be explained by the delay in the first clinical manifestations as described in previous studies [11] which shows the importance of family studies for preventive follow-up [12, 13].

The clinical symptoms in our cohort were similar to the classical findings in Pompe disease studies [14, 15]. We confirm that the most common symptom in LOPD is muscle weakness and it was present in all patients except the asymptomatic ones because they are early diagnosis prescribed for family study. Elevated CPK levels and respiratory distress were the next most frequent symptoms. Myalgia, dysphagia or hypotonia were less frequent symptoms in our population (12.5%). Patient #1 [two days of age], showed an hypertrophic cardiomyopathy, the most frequent manifestation in IOPD as reported in literature. PD presents a great clinical heterogeneity, even in patients with the same mutation. Therefore, the type and degree of manifestations of each individual could depend on the residual enzymatic activity and its interaction with other genetic or epigenetic factors.

In accordance with others studies, our results confirm that the mutations are distributed throughout the entire gene. [17, 18]. As published in the bibliography, the gene has three critical regions: exon 2, which includes start codon, exon 10 and 11 where the evolutionarily conserved catalytic site domain is contained, and exon 14 which includes a widely conserved region. Two variants of our study were detected in exon 2, none in exons 10, 11 or 14. The rest of the variants are distributed by almost all exons as shown in the table 2. Due to the NGS boom, it is expected that more variants of uncertain significance will be explained in the future.

Sequence analysis of the complete coding region of the GAA gene revealed 14 different variants from 17 patients including nine missense mutations (26.4%), one nonsense mutation (2.9%), three deletion or insertion (17.6%), eighteen splicing variants (52.9%).

Similar to other studies, the splice-site mutation c.32-13T > G was the most frequent mutation found in our cohort. As is published in the literature, the intronic variant is the most common in Caucasian populations and it is present in 40–70% of the alleles in patients affected with PD [2]. In this study, it was seen in all patients except patient #1 and patient #5 (17 alleles, 50%). Patient #13 and patient #16 presented the variant in homozygosis. This variant is located in the 3’ splice region and it causes aberrant splicing of the GAA gene. For this reason, the splicing variant c.-32-13T > G is considered pathogenic [19–21].

The next most frequent mutation present in our population was c.236_246delCCACACGTGC. It was described by Palmer [22] in a patient who presented a severe infantile-onset Pompe disease. In concordance with the previous study, we encountered the deletion in homozygosis in patient #1. Patient #1 had a sister with diagnosed PD who died at nine months of age and for whom we do not have
the results of the genetic study, the clinical information refers to parents as carriers of the disease. It was found too in heterozygosis in patient #10, a forty-six years old man. The presence of the homozygous variant could be established as providing a more serious effect or being indicative of a worse prognosis.

The mutation c.1396_1397insG was identified in two heterozygotes patients, they were asymptomatic sisters (patient #2 and #3) who showed the same genotype (c.-32-13T > G + c.1396_1397insG) very young to present the PD clinical symptoms (7 and 9 years old respectively). The variant is described as cause of PD creating a frame shift starting at codon Val466 and a stop codon in 39 position downstream [23]. The rest of the variants (c.281_282delCT; c.655G > A; c.875A > G; c.925G > A; c.1655T > C; c.2104C > T; c.2237G > C) had already been described in the literature as pathogenic were shown only once and, therefore, were less frequent in our population.

This study contributed to the identification of four new probably pathogenic variants which had not been described previously in the literature (c.1328A > T; c.1831G > A; c.1889-1G > A).

The substitution c.1328A > T (p.Asp443Val) was detected in exon 9 of patient #5. The missense variant produces a change in the protein and replaces aspartic acid with valine at codon 443. There are physicochemical differences between these amino acids. Acid aspartic is neutral and polar and valine is neutral and non-polar. This could modify the conformation of the protein and affect its function. Other missense variants have been reported as pathogenic in nearby codons [24, 25]. This findings suggests that this variant contributes to disease.

The missense variant c.1831G > A is located in exon 13 and it was shown in heterozygosis in patient #4. This substitution (p.Gly611Ser) replaces glycine with serine at codon 611. Glycine is non-polar and serine is polar. These physicochemical differences can alter the structure of the protein and could affect its function. On the other hand, it is the second variant discovered in this codon. The mutation c.1832G > A (p.Gly611Asp), which also change glycine for a polar amino acids, was described in previous study and was reported as pathogenic variant [26].

We detected the nonsense variant c.2819C > A in patient #9. This variant generates a slightly truncated protein (p.Ser940Ter). It was assumed to be deleterious since the stop codons of other proteins were detected upstream of this and were known to result in a complete loss of enzyme activity. The variant c.2741delinsCAG [p.Gln944*fs30] produces a premature stop codon in aminoacid 944, was previously described by van Gelder [27]. in patients that did not present any activity of α-glucosidase. This leads us to think that a previous stop codon will also generate damage to the protein.

The splicing variant c.1889-1G > A in the intron 13 was detected in patient #11. As Anna [28] published, in general, mutations in the canonical acceptor and donor sites affect strongly conserved sequences that define exon-intron boundaries. Therefore, any variants in these canonical sequences might alter interaction between premRNA and proteins involved in the intron removal.

**Conclusions**

In this study fourteen genetic variants in GAA gene were identified, as cause of Pompe disease, including four new variants. This study confirms that patients in Spain have a characteristic profile of a European population, with c.-32-13T > G being the most prevalent variant. Furthermore, it was confirmed that the c.236_246delCCACACAGTGC mutation in homozygosy is associated with early disease and a worse prognosis. We propose to extend the genetic study in the 7 individuals without genetic justification using techniques that require the study of the intronic zones of the gene or alfa-glucosidase messenger RNA.

Our findings underscore the importance of early diagnosis and propose to accurate molecular analysis to improve genetic counseling in addition to enabling a better quality of life for patients.

**Declarations**

*Ethics approval and consent to participate*

Informed consent was signed by all patients and the study was approved by the Ethics and Research Committee of the Virgen Macarena and Virgen del Rocío University Hospital (Code: 0826-N-15).

*Consent for publication*
Availability of data and materials

No sé qué poner aquí

Competing interests

The authors declare that they have no competing interests

Funding

Not applicable

Authors’ contributions

Paula Hernández-Arevalo has written the article and has contributed to the diagnosis and analysis of the cases. Rocío Delarosa-Rodríguez has contributed to the diagnosis and analysis of the cases. Pilar Jiménez-Arriscado is the expert technician who realize all the genetic libraries. Antonio González-Meneses and Salvador García-Morillo have contributed to the recruitment of patients and the interpretation of clinical symptoms. José D. Santotoribio and Hada C. Macher are in charge of the molecular diagnostic laboratory and have reviewed all the diagnostic and results analysis processes for clinical validation and Juan M. Guerrero is the head of the department of clinical biochemistry and professor at the University of Seville, he is the main researcher of the laboratory projects and has supervised and approved the entire process.

Acknowledgements

No se qué poner aquí

References

1. Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y, Rom WN, et al. Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet. 1998;79(1):69–72.
2. Peruzzo P, Pavan E, Dardis A. Molecular genetics of Pompe disease: a comprehensive overview. Ann Transl Med. 2019;7(13):278.
3. Yang CC, Chien YH, Lee NC, et al. Rapid progressive course of later-onset Pompe disease in Chinese patients. Mol Genet Metab. 2011;104(3):284–8.
4. Liu X, Wang Z, Jin W, et al. Clinical and GAA gene mutation analysis in mainland Chinese patients with late-onset Pompe disease: identifying c.2238G > C as the most common mutation. BMC Med Genet. 2014;15:141.
5. Chamoles NA, Niizawa G, Blanco M, Gaggioli D, Casentini C. Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper. Clin Chim Acta. 2004;347(1–2):97–102.
6. Zhang H, Kallwass H, Young SP, et al. Comparison of maltose and acarbose as inhibitors of maltase-glucoamylase activity in assaying acid alpha-glucosidase activity in dried blood spots for the diagnosis of infantile Pompe disease. Genet Med. 2006;8(5):302–6.
7. Jack RM, Gordon C, Scott CR, Kishnani PS, Bali D. The use of acarbose inhibition in the measurement of acid alpha-glucosidase activity in blood lymphocytes for the diagnosis of Pompe disease. Genet Med. 2006;8(5):307–12.
8. Preiser N, Lukacs Z, Vinge L, et al. Late-onset Pompe disease is prevalent in unclassified limb-girdle muscular dystrophies. Mol Genet Metab. 2013;110(3):287–9.
9. Spada M, Porta F, Vercelli L, Pagliardini V, Chiadò-Piat L, Boffi P, Pagliardini S, Remiche G, Ronchi D, Comi G, Mongini T. Screening for later-onset Pompe's disease in patients with paucisymptomatic hyperCKemia. Mol Genet Metab. 2013 Jun;109(2):171–3.
10. Leslie N, Bailey L. Pompe Disease. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews®. Seattle (WA): University of Washington; August 31, 2007.
11. Kohler L, Puertollano R, Raben N. Pompe Disease: From Basic Science to Therapy. Neurotherapeutics. 2018;15(4):928–42.
12. Hagemans ML, Winkel LP, Van Doom PA, et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain. 2005;128(Pt 3):671–7.
13. Müller-Felber W, Horvath R, Gempel K, et al. Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord. 2007;17(9–10):698–706.

14. Angelini C, Semplicini C, Ravaglia S, et al. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol. 2012;259(5):952–8.

15. Toscano A, Rodolico C, Musumeci O. Multisystem late onset Pompe disease (LOPD): an update on clinical aspects. Ann Transl Med. 2019;7(13):284.

16. van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332–40.

17. Montalvo AL, Bembi B, Donnarumma M, et al. Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat. 2006;27(10):999–1006.

18. McCready ME, Carson NL, Chakraborty P, et al. Development of a clinical assay for detection of GAA mutations and characterization of the GAA mutation spectrum in a Canadian cohort of individuals with glycogen storage disease, type II. Mol Genet Metab. 2007;92(4):325–35.

19. Wens SC, van Gelder CM, Kruijshaar ME, et al. Phenotypical variation within 22 families with Pompe disease. Orphanet J Rare Dis. 2013;8:182. Published 2013 Nov 19.

20. Herzog A, Hartung R, Reuser AJ, et al. A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations. Orphanet J Rare Dis. 2012;7:35. Published 2012 Jun 7.

21. Montagnese F, Barca E, Musumeci O, et al. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment. J Neurol. 2015;262(4):968–78.

22. Palmer RE, Amartino HM, Niizawa G, Blanco M, Pomponio RJ, Chamoses NA. Pompe disease (glycogen storage disease type II) in Argentinians: clinical manifestations and identification of 9 novel mutations. Neuromuscul Disord. 2007;17(1):16–22.

23. Jones LK Jr, Liewluck T, Gavrilova RH. Myalgic phenotype and preserved muscle strength in adult-onset acid maltase deficiency. Neuromuscul Disord. 2012;22(8):763–6.

24. Park YE, Park KH, Lee CH, Kim CM, Kim DS. Two new missense mutations of GAA in late onset glycogen storage disease type II. J Neurol Sci. 2006;251(1–2):113–7.

25. Lam CW, Yuen YP, Chan KY, et al. Juvenile-onset glycogen storage disease type II with novel mutations in acid alpha-glucosidase gene. Neurology. 2003;60(4):715–7.

26. Bali DS, Goldstein JL, Banugaria S, et al. Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience. Am J Med Genet C Semin Med Genet. 2012;160C(1):40–9.

27. van Gelder CM, Hoogeveen-Westerveld M, Kroos MA, Plug I, van der Ploeg AT, Reuser AJ. Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease. J Inherit Metab Dis. 2015;38(2):305–14. doi:10.1007/s10545-014-9707-6.

28. Anna A, Monika G. Splicing mutations in human genetic disorders: examples, detection, and confirmation [published correction appears in J Appl Genet. 2019 May;60(2):231]. J Appl Genet. 2018;59(3):253–268.

29. Huie ML, Chen AS, Tsujino S, et al. Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T–>G) mutation in a majority of patients and a novel IVS10 (+ 1GT–>CT) mutation. Hum Mol Genet. 1994;3(12):2231–6.

30. Palmer RE, Amartino HM, Niizawa G, Blanco M, Pomponio RJ, Chamoses NA. Pompe disease (glycogen storage disease type II) in Argentinians: clinical manifestations and identification of 9 novel mutations. Neuromuscul Disord. 2007;17(1):16–22.

31. Fernandez-Hojas R, Huie ML, Navarro C, et al. Identification of six novel mutations in the acid alpha-glucosidase gene in three Spanish patients with infantile onset glycogen storage disease type II (Pompe disease) [published correction appears in Neuromuscul Disord. 2003 Jun;13(5):427]. Neuromuscul Disord. 2002;12(2):159–166.

32. Hermans MM, van Leenen D, Kroos MA, et al. Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat. 2004;23(1):47–56.

33. Castro-Gago M, Eirís-Puñal J, Rodríguez-Núñez A, Pintos-Martínez E, Bencloch-Marín T, Barros-Angueira F. Forma grave de glucogenosis tipo II juvenil en un niño heterocigoto compuesto (Tyr-292–>Cys/Arg-854–>Stop) [Severe form of juvenile type II
glycogenosis in a compound-heterozygous boy (Tyr-292→ Cys/Arg-854→ Stop)]. Rev Neurol. 1999;29(1):46–9.

34. Kroos MA, van Leenen D, Verbiest J, Reuser AJ, Hermans MM. Glycogen storage disease type II: identification of a dinucleotide deletion and a common missense mutation in the lysosomal alpha-glucosidase gene. Clin Genet. 1998;53(5):379–82.

35. Bodamer OA, Haas D, Hermans MM, Reuser AJ, Hoffmann GF. L-alanine supplementation in late infantile glycogen storage disease type II. Pediatr Neurol. 2002 Aug;27(2):145–6.

36. Huie ML, Menaker M, McAlpine PJ, Hirschhorn R. Identification of an E689K substitution as the molecular basis of the human acid alpha-glucosidase type 4 allozyme (GAA*4). Ann Hum Genet. 1996 Sep;60(5):365–8.

37. Montalvo AL, Cariati R, Deganuto M, Guerci V, Garcia R, Ciana G, Bembi B, Pittis MG. Glycogenosis type II: identification and expression of three novel mutations in the acid alpha-glucosidase gene causing the infantile form of the disease. Mol Genet Metab.

38. Montalvo AL, Bembi B, Donnarumma M, Filocamo M, Parenti G, Rossi M, Merlini L, Buratti E, De Filippi P, Dardis A, Stroppiano M, Ciana G, Pittis MG. Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II. Hum Mutat. 2006 Oct;27(10):999–1006.

39. Kroos M, Pomponio RJ, van Vliet L, Palmer RE, Phipps M, Van der Helm R, Halley D, Reuser A, GAA Database Consortium. Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat. 2008 Jun;29(6):E13–26.

**Tables**

Table 1. Clinical and biochemical analysis information of 17 patients of PD and 2 individuals with a single variant. F: female; M: male; B: biopsy; FM: Family member; A: asymptomatic; 1: Cardiomyopathy; 2: HyperCKemia; 3: Muscle weakness; 4: Exercise intolerance; 5: Hipotoni; 6: Myalgia; 7: Dysphagia; 8: Respiratory distress; 9: Dyspnoea.
| Subject | Age | Sex | Symptoms or Signs | GAA activity | Lymphocytes | Variant 1 | Variant 2 |
|---------|-----|-----|------------------|--------------|-------------|-----------|-----------|
| #1      | 0   | M   | 1 FM             | 0.5          | N/A         | c.236_246delCCACACAGTGC | c.236_246delCCACACAGTGC |
| #2      | 7   | F   | A FM             | 0.12         | 0.01        | c.-32-13T>C          | c.1396_1397insG         |
| #3      | 9   | F   | A FM             | 0.15         | 0.07        | c.-32-13T>C          | c.1396_1397insG         |
| #4      | 11  | F   | 1 2 3            | 0.16         | 0.03        | c.-32-13T>C          | c.1831G>A               |
| #5      | 17  | F   | 2 3 4 B          | 0.37         | 0.02        | c.1328A>T            | c.1328A>T               |
| #6      | 19  | M   | A F              | 0.37         | 0.05        | c.-32-13T>C          | c.281_282delCT          |
| #7      | 31  | M   | 23               | 0.27         | 0.05        | c.-32-13T>C          | c.1655T>C               |
| #8      | 32  | F   | 23               | 0.3          | 0.09        | c.-32-13T>C          | c.925G>A                |
| #9      | 44  | F   | 18               | 0.34         | N/A         | c.-32-13T>C          | c.2819C>A               |
| #10     | 46  | M   | 3 4 5            | 0.36         | 0           | c.-32-13T>C          | c.236_246delCCACACAGTGC |
| #11     | 51  | M   | 2 3 6 7          | 0.21         | 0.04        | c.-32-13T>C          | c.2104C>T               |
| #12     | 52  | M   | 38               | 0.48         | 0.01        | c.-32-13T>C          | c.1889-1G>A             |
| #13     | 57  | F   | 3 4 9            | 0.37         | 0.01        | c.-32-13T>C          | c.2237G>C               |
| #14     | 58  | F   | 35               | 0.33         | 0.1         | c.-32-13T>C          | c.-32-13T>C             |
| #15     | 58  | M   | 234              | 0.31         | 0.11        | c.-32-13T>C          | c.655G>A                |
| #16     | 59  | H   | 2 3 8            | 0.17         | 0.01        | c.-32-13T>C          | c.-32-13T>C             |
| #17     | 64  | M   | 2 3 6 7          | 0.54         | 0.1         | c.-32-13T>C          | c.875A>G                |
| #18     | 79  | F   | A FM             | 0.65         | 0.11        | c.854C>G             | -                      |
| #19     | 63  | M   | 2 3              | 0.47         | 0.06        | c.2065G>A            | -                      |

Table 2. Type and frequency of GAA variants of the patients.
| Nucleotide change | Effect on protein | Location | Frequency |
|------------------|------------------|----------|-----------|
| c.655G>A         | p.Gly219Arg      | Exon 3   | 1/36      |
| c.854C>G         | p.Pro285Arg      | Exon 4   | 1/36      |
| c.875A>G         | p.Tyr292Cys      | Exon 5   | 1/36      |
| c.925G>A         | p.Gly309Arg      | Exon 5   | 1/36      |
| c.1328A>T        | p.Asp443Val      | Exon 9   | 2/36      |
| **Missense**     |                  |          |           |
| c.1655T>C        | p.Leu552Pro      | Exon 12  | 1/36      |
| c.1831G>A        | p.Gly611Ser      | Exon 13  | 1/36      |
| c.2104C>T        | p.Arg702Cys      | Exon 13  | 1/36      |
| c.2065G>A        | p.Glu689Lys      | Exon 15  | 1/36      |
| c.2237G>C        | p.Trp746Ser      | Exon 16  | 1/36      |
| **Nonsense**     |                  |          |           |
| c.2819C>A        | p.Ser940Ter      | Exon 20  | 1/36      |
| **Deletion or insertion** |                  |          |           |
| c.236_246delCCACACAGTGC | p.Pro79fs     | Exon 2   | 3/36      |
| c.281_282delCT   | p.Pro94fs        | Exon 2   | 1/36      |
| c.1396_1397insG  | p.Val466fs       | Exon 9   | 2/36      |
| **Splicing variant** |                  |          |           |
| c.-32-13T>C      | -                | Intron 1 | 17/36     |
| c.1889-1G>A      | -                | Intron 13| 1/36      |

Table 3. Analysis of variants by bibliography and in silico predictive tools.
| Nucleotide change       | Effect on protein | ClinVar   | Mutation Taster | PolyPhen-2 | HGMD | Pompe database  |
|------------------------|-------------------|-----------|-----------------|-------------|------|----------------|
| **Described mutations**|                   |           |                 |             |      |                |
| c.-32-13T>C            |                   | Pathogenic|                 |             | 29   | Potentially mild|
| c.236_246delCCACACAGTGC| p.Pro79fs         | Pathogenic| Disease causing |             | 30   | Very severe     |
| c.281_282delCT         | p.Pro94fs         | Likely pathogenic| Disease causing |             |      |                |
| c.655G>A               | p.Gly219Arg       | Pathogenic| Disease causing |             | 31   | Potentially less severe |
| c.854C>G               | p.Pro285Arg       | Pathogenic| Disease causing |             | 32   | Potentially mild |
| c.875A>G               | p.Tyr292Cys       | Pathogenic| Disease causing |             | 33   | Potentially mild |
| c.925G>A               | p.Gly309Arg       | Pathogenic| Disease causing |             | 34   | Potentially less severe |
| c.1396_1397insG        | p.Val466fs        | Not described | Disease causing |             |      |                |
| c.1655T>C              | p.Leu552Pro       | Pathogenic| Disease causing |             | 35   | Potentially less severe |
| c.2065G>A              | p.Glu689Lys       | Conflicts of interpretation | Polymorphism | Likely benign | 36   |                |
| c.2104C>T              | p.Arg702Cys       | Pathogenic| Disease causing |             | 37, 38 | Potentially less severe |
| c.2237G>C              | p.Trp746Ser       | Not described | Disease causing |             | 39   | Potentially less severe |
| **Novel mutations**    |                   |           |                 |             |      |                |
| c.1328A>T              | p.Asp443Val       | Not described | Disease causing |             |      |                |
| c.1831G>A              | p.Gly611Ser       | Not described | Disease causing |             |      |                |
| c.1889-1G>A            |                   | Not described | Disease causing |             |      |                |
| c.2819C>A              | p.Ser940Ter       | Not described | Disease causing |             |      |                |

**Figures**
Figure 1

A description of PD screening protocol.
Figure 2

Enzyme activity values in DBS and lymphocytes in patients.

Figure 3
Evolutionary conservation of amino acids by missense mutation across different species and position of the residues involved in the structure of human GAA. A: variant c.1328A>T; B: variant c.1831G>A